Although accumulating evidence suggests that CD44 plays a key role in the clinicopathological features of numerous cancers,290, 291 there are relatively few clinical studies designed to evaluate the efficacy of CD44‐targeted therapies in cancer treatment. This evidence concerns the gene CD44 and cancer.